Search Results - "Brookes, Jody"

Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD by Monk, Phillip D, Brookes, Jody L, Tear, Victoria J, Batten, Toby N, Newall, Clare, Mankowski, Marcin, Crooks, Michael G, Singh, Dave, Chaudhuri, Rekha, Leaker, Brian, Lunn, Kerry, Reynolds, Sophie, Dudley, Sarah, Gabbay, Felicity J, Holgate, Stephen T, Djukanovic, Ratko, Wilkinson, Thomas Ma

“…Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to…”
Get full text

Feasibility of home administration of nebulised interferon ß-1a (SNG001) for COVID-19: a remote study by Francis, Nick A, Monk, Phillip D, Nuttall, Jacqueline, Oliver, Thomas, Simpson, Catherine, Brookes, Jody L, Tear, Victoria J, Thompson, Angela G, Batten, Toby N, Mankowski, Marcin, Wilkinson, Thomas Ma

“…Effective therapeutics given early to high-risk ambulatory patients with coronavirus disease 2019 (COVID-19) could improve outcomes and reduce overall…”
Get full text

Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study by Monk, Phillip D, Brookes, Jody L, Tear, Victoria J, Batten, Toby N, Mankowski, Marcin, Adzic-Vukicevic, Tatjana, Crooks, Michael G, Dosanjh, Davinder P S, Kraft, Monica, Brightling, Christopher E, Gabbay, Felicity J, Holgate, Stephen T, Djukanovic, Ratko, Wilkinson, Tom M A

“…Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally…”
Get full text

Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study by Monk, Phillip D, Brookes, Jody L, Tear, Victoria J, Batten, Toby N, Mankowski, Marcin, Adzic-Vukicevic, Tatjana, Crooks, Michael G, Dosanjh, Davinder PS, Kraft, Monica, Brightling, Christopher E, Gabbay, Felicity J, Holgate, Stephen T, Djukanovic, Ratko, Wilkinson, Tom MA

Get full text

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial by Monk, Phillip D, Marsden, Richard J, Tear, Victoria J, Brookes, Jody, Batten, Toby N, Mankowski, Marcin, Gabbay, Felicity J, Davies, Donna E, Holgate, Stephen T, Ho, Ling-Pei, Clark, Tristan, Djukanovic, Ratko, Wilkinson, Tom M A, Crooks, Michael G, Dosanjh, Davinder PS, Siddiqui, Salman, Rahman, Najib M, Smith, Jacklyn A, Horsley, Alexander, Harrison, Timothy W, Saralaya, Dinesh, McGarvey, Lorcan, Watson, Alastair, Foster, Edmund, Fleet, Adam, Singh, Dave, Hemmings, Sophie, Aitken, Sandra, Dudley, Sarah, Beegan, Rona, Thompson, Angela, Rodrigues, Pedro MB

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are…”
Get full text

LB1533. Impact of Treatment of Hospitalised COVID-19 Patients With Inhaled Interferon Beta-1a (SNG001) on Long COVID Symptoms: Results From the SPRINTER trial by Monk, Phillip D, Evans, Rachael A, Tear, Victoria J, Brookes, Jody L, Batten, Toby, Mankowski, Marcin, Djukanovic, Ratko, Holgate, Stephen T, Brightling, Chris, Wilkinson, Tom

Get full text

375. The Effect of Inhaled Interferon Beta-1a (SNG001) Treatment Compared to Placebo on Lung Antiviral Biomarkers and Viral Clearance in Chronic Obstructive Pulmonary Disease (COPD) Patients With Respiratory Virus Infections by Monk, Phillip D, Brookes, Jody L, Tear, Victoria J, Batten, Toby, Newall, Clare, Mankowski, Marcin, Crooks, Michael G, Singh, Dave, Chaudhuri, Rekha, Lunn, Kerry, Reynolds, Sophie, Dudley, Sarah, Gabbay, Felicity, Holgate, Stephen T, Djukanovic, Ratko, Wilkinson, Tom

Get full text